Filtered By:
Condition: Rheumatoid Arthritis
Infectious Disease: Herpes
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
This study is active but not recruiting and is registered with ClinicalTrials.gov, number NCT02706951.FindingsPatients were screened between Feb 23, 2016, and May 19, 2017 and 648 were randomly assigned to treatment. 598 (92%) completed week 14. At week 14, an ACR20 response was achieved by 89 (41%) of 216 patients (95% CI 35–48) in the continued methotrexate group, 147 (68%) of 217 patients (62–74) receiving upadacitinib 15 mg, and 153 (71%) of 215 patients (65–77) receiving upadacitinib 30 mg (p<0·0001 for both doses vs continued methotrexate). DAS28(CRP) 3·2 or lower was met by 42 (19%) of 216 (95% CI 14–2...
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research
The Importance of CXCL1 in Physiology and Noncancerous Diseases of Bone, Bone Marrow, Muscle and the Nervous System
Int J Mol Sci. 2022 Apr 11;23(8):4205. doi: 10.3390/ijms23084205.ABSTRACTThis review describes the role of CXCL1, a chemokine crucial in inflammation as a chemoattractant for neutrophils, in physiology and in selected major non-cancer diseases. Due to the vast amount of available information, we focus on the role CXCL1 plays in the physiology of bones, bone marrow, muscle and the nervous system. For this reason, we describe its effects on hematopoietic stem cells, myoblasts, oligodendrocyte progenitors and osteoclast precursors. We also present the involvement of CXCL1 in diseases of selected tissues and organs including A...
Source: Herpes - April 23, 2022 Category: Infectious Diseases Authors: Jan Korbecki Magdalena G ąssowska-Dobrowolska Jerzy W ójcik Iwona Szatkowska Katarzyna Barczak Miko łaj Chlubek Irena Baranowska-Bosiacka Source Type: research
Safety of JAK inhibitors: a real-life multicenter retrospective cohort study
CONCLUSION: Our real-life data confirm that JAKi are effective and carry a low risk of AESI, especially in patients that do not display cardiovascular risk factors at baseline. Our study could not identify differences between molecules and different profiles should be defined in larger prospective cohorts.PMID:37527867 | DOI:10.3899/jrheum.2023-0145
Source: Journal of Rheumatology - August 1, 2023 Category: Rheumatology Authors: Marco Lanzillotta Nicola Boffini Elisa Barone Gilberto Cincinelli Maria Chiara Gerardi Nicoletta Luciano Maria Manara Nicola Ughi Oscar Massimiliano Epis Carlo Selmi Roberto Felice Caporali Lorenzo Dagna Source Type: research
